Pelkonen R, Taskinen M R, Nikkilä E A
Int J Obes. 1977;1(4):315-24.
The early response of plasma insulin (IRI) to successive intravenous doses of 50, 100 and 200 mg of tolbutamide was studied in nondiabetic obese subjects, in acromegalic patients, and in healthy controls. The smallest dose raised the plasma IRI level within two minutes in all subjects. The insulin response was correlated with the basal IRI in controls and in obese subjects but not in acromegalic patients. At each tolbutamide dose level the mean IRI response of obese subjects was about three times greater than in controls. In acromegalic subjects an increased response was observed only after the 200 mg dose of tolbutamide. The results suggest that in obesity the stimulus-secretion coupling of insulin output is normal but the number of secretory units is increased. In acromegaly the insulin release pattern is compatible with an increased number of secretory units which, however, are relatively insensitive to tolbutamide, probably due to an elevated serum growth hormone level.
在非糖尿病肥胖受试者、肢端肥大症患者和健康对照者中,研究了血浆胰岛素(IRI)对连续静脉注射50、100和200毫克甲苯磺丁脲的早期反应。最小剂量在两分钟内使所有受试者的血浆IRI水平升高。胰岛素反应在对照组和肥胖受试者中与基础IRI相关,但在肢端肥大症患者中不相关。在每个甲苯磺丁脲剂量水平,肥胖受试者的平均IRI反应比对照组大约大三倍。在肢端肥大症受试者中,仅在200毫克甲苯磺丁脲剂量后观察到反应增加。结果表明,在肥胖症中,胰岛素分泌的刺激-分泌偶联是正常的,但分泌单位的数量增加。在肢端肥大症中,胰岛素释放模式与分泌单位数量增加一致,然而,这些分泌单位对甲苯磺丁脲相对不敏感,可能是由于血清生长激素水平升高。